- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Methotrexate and Hydroxychloroquine Combo may significantly Improve Outcomes in Rheumatoid Arthritis: Study
A recent study published in the International Journal of Rheumatic Diseases compared the efficacy and safety of combination therapy with methotrexate (MTX) plus hydroxychloroquine (HCQ) versus MTX monotherapy in patients with rheumatoid arthritis (RA) and found promising results. The study included a total of 60 patients and were randomly divided into 2 groups. One group received a combination of MTX and HCQ, while the other received only MTX.
Both groups were monitored for 12 weeks, with data collected on several key measures like pain intensity using the visual analogue scale (VAS), disease activity score (DAS) in 28 joints, serum inflammatory markers such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). The World Health Organization Quality of Life Brief Version questionnaire (WHOQOL-BREF) was also used to assess quality of life. Adverse reactions were recorded throughout the trial to gauge safety.
At the end of the 12-week trial, the group treated with the combination of MTX and HCQ demonstrated significantly greater improvements across all evaluated parameters when compared to the group receiving MTX monotherapy. The patients on combination therapy experienced a more notable decrease in pain scores than the patients on MTX alone. This suggests that the addition of HCQ may provide improved relief from the chronic discomfort associated with RA.
The combination therapy group showed a more substantial reduction in disease activity which indicated a better control of joint inflammation and swelling. Serum levels of CRP, ESR, IL-6, and TNF-α were significantly reduced in patients who were receiving the combination treatment that reflected lower systemic inflammation. These results suggest that HCQ, in combination with MTX, has a synergistic anti-inflammatory effect that helps better manage the underlying disease processes.
WHOQOL-BREF scores were higher in the MTX + HCQ group, this indicates that patients on combination therapy experienced greater improvements in overall well-being and functionality. This highlights the potential for better long-term outcomes when HCQ is included in the treatment regimen.
While both treatment groups reported some adverse reactions, the overall incidence was low, with 10% in the combination therapy group and 6.67% in the MTX monotherapy group. Also, there was no statistically significant difference in the rate of adverse events between the 2 groups, suggesting that the addition of HCQ does not substantially increase the risk of side effects. Overall, this study found that combination therapy with MTX and HCQ offers superior outcomes in terms of pain relief, disease activity reduction, inflammation control, and quality of life when compared to MTX monotherapy.
Reference:
Ma, J., Zeng, M., Hsu, C., Li, D., Fok, M. N., Jiang, Y., Li, Q., Ma, J., Zhou, J., Chen, B. S., & Li, F. (2024). Efficacy and safety of methotrexate plus hydroxychloroquine combination therapy vs. methotrexate monotherapy in the treatment of rheumatoid arthritis: A randomized controlled clinical trial. In International Journal of Rheumatic Diseases (Vol. 27, Issue 9). Wiley. https://doi.org/10.1111/1756-185x.15319
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751